Delivery Order SPE2DR25D9239-SPE2DR26FFCV5
- Not listed
- The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on April 22, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 10 mg tablets (60-count units), with an ultimate completion date of April 23, 2026. PPV-G GEN V is a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling through December 31, 2036, structured with a 30-month base period and three 30-month option...
- The Defense Logistics Agency issued a $16,526.95 delivery order to DMS Pharmaceutical Group Inc. on March 10, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 10 mg tablets (60-count). PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for pharmaceutical products and medical consumables supporting Department of Defense healthcare operations worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business...
- The Defense Logistics Agency issued a $25,326.56 delivery order to DMS Pharmaceutical Group Inc. on April 27, 2026, for JAKAFI 10 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables supporting Department of Defense military...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 6, 2026, for $50,653.12 (ceiling value) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of JAKAFI 10 mg tablets (60-count). PPV-G GEN V is a Defense Logistics Agency single-award Indefinite Delivery Contract authorizing firm fixed-price delivery orders for pharmaceutical products, biologics, and medical consumables to support Department of Defense military...
- The Defense Logistics Agency issued a $25,165.90 delivery order to DMS Pharmaceutical Group Inc. on April 22, 2026, for JAKAFI 15 MG tablets under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for branded and generic prescription drugs, biologics, over-the-counter medications, vaccines, and medical consumables supporting Department of Defense military healthcare facilities...
- The Defense Logistics Agency issued a $12,582.95 delivery order to DMS Pharmaceutical Group Inc. on March 16, 2026, for JAKAFI 15 mg tablets (60-count) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is the Defense Logistics Agency's comprehensive pharmaceutical supply contract supporting Department of Defense healthcare operations globally with branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables....
- The Defense Logistics Agency issued a $37,989.81 delivery order to DMS Pharmaceutical Group Inc. on April 27, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of JAKAFI 10 mg tablets (60-count units). PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for branded and generic prescription drugs, biologics, over-the-counter medications, vaccines, and medical consumables to Department of Defense military healthcare...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on April 3, 2026, for JAKAFI 10 mg tablets (60 count) with a ceiling value of $12,663.27 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency single-award indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products, biologics, and medical consumables supporting Department of Defense military...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on April 17, 2026, for JAKAFI 10 mg tablets (60-count), with a ceiling value of $75,979.68 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract for pharmaceutical and medical consumable supply to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical is the sole...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 25, 2026, for $12,663.27, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) parent contract for supply of JAKAFI 10 mg tablets (60-count units). PPV-G GEN V is a Defense Logistics Agency initiative authorizing firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support...
- SPE2DR25D9239Indefinite Delivery Contract
- SPE2DR25D9239-SPE2DR26FFCV5Delivery Order
The Defense Logistics Agency issued a $25,165.90 delivery order to DMS Pharmaceutical Group Inc. on April 29, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for JAKAFI 15 MG tablets (60-count units). PPV-G GEN V is a single-award indefinite delivery contract through which the Defense Logistics Agency authorizes firm fixed-price delivery orders for pharmaceutical products and medical consumables supporting Department of Defense military healthcare facilities worldwide, including domestic and overseas locations. The contract carries a $499.999 billion ceiling and runs through December 31, 2036. Place of performance is Park Ridge, Illinois. Ultimate completion date for this order is April 30, 2026. DMS Pharmaceutical Group Inc. is a woman-owned small business.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.2k | 4/28/26 |